Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review

ISSN： 1473-7167

Source： Expert Review of Pharmacoeconomics and Outcomes Research, Vol.13, Iss.2, 2013-04, pp. : 171-182

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness

By Clegg A. Bryant J.

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 4, 2001-04 ,pp. : 623-639

Informa Healthcare

Access to resources Recommend Favorite

Cost-Effectiveness Analyses of Natalizumab (Tysabri ® ) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

By Gani Ray

PharmacoEconomics, Vol. 26, Iss. 7, 2008-01 ,pp. : 617-627

Adis International

Access to resources Recommend Favorite

A systematic review of cost-effectiveness analyses of pharmacogenomic interventions

By Phillips Kathryn A Van Bebber Stephanie L

Pharmacogenomics, Vol. 5, Iss. 8, 2004-12 ,pp. : 1139-1149

Future Medicine

Access to resources Recommend Favorite

Cost-Effectiveness of Interventions to Enhance Medication Adherence in Psychiatric Patients: A Systematic Review

Current Clinical Pharmacology, Vol. 6, Iss. 2, 2011-01 ,pp. : 115-124

Bentham Science Publishers

Access to resources Recommend Favorite

Natalizumab: multiple benefits in multiple sclerosis

Inpharma, Vol. 1, Iss. 1487, 2005-01 ,pp. : 9-11

Adis International

Access to resources Recommend Favorite